Prostate Cancer Retreatment Shows Promise in New Study
Patients with metastatic prostate cancer may find a safe option for further radioligand therapy in preliminary phase 2 findings.
Updated on Oct. 24, 2026 in Cancer
Live Poll
Do you believe the potential benefits of new cancer therapies justify their reported side effects?
The Re-LuPSMA phase 2 trial has met safety thresholds for retreatment with the radioligand therapy lutetium Lu 177 vipivotide tetraxetan in patients with metastatic castration-resistant prostate cancer. This preliminary study evaluated the safety of offering additional doses to patients who previously responded to the treatment.
Why it matters
For patients with advanced prostate cancer who have already seen success with this therapy, finding safe options for retreatment is a critical clinical goal. The current results suggest that additional cycles may be viable for some patients, though long-term efficacy and safety remain under study.
In a phase 2 study of 19 patients with metastatic castration-resistant prostate cancer, researchers recorded 88 possibly treatment-related adverse effects. The trial did not reach its stopping threshold of 5 serious treatment-related adverse events, though these are preliminary findings.
The players
UCLA
A major research institution that hosted the Re-LuPSMA clinical trial for prostate cancer treatment.
The details
The treatment works by delivering targeted radiation directly to cancer cells that express the prostate-specific membrane antigen (PSMA) protein. To receive retreatment, participants must have completed 4 to 6 cycles of initial therapy and show a 50% decline in prostate-specific antigen (PSA) levels. Before additional cycles, patients undergo PSMA PET imaging to confirm eligibility, with the current group receiving a median of 3 retreatment cycles.
Timeline
July 2026: FDA approved lutetium Lu 177 vipivotide tetraxetan for hormone-sensitive cancer.
October 24, 2026: Interim safety data was presented at the ESMO Congress.
Health Landscape
This study expands upon the established role of radioligand therapy in treating advanced prostate cancer. It follows an arc of research aimed at determining how to safely extend therapeutic benefits through retreatment and planned treatment holidays.
Patients currently undergoing treatment for metastatic castration-resistant prostate cancer should talk to their oncologist about the latest clinical trial developments. Questions about whether retreatment options are appropriate for your specific clinical history are best addressed during your regular follow-up visits.
The takeaway
Preliminary data suggest that retreatment with this radioligand may be manageable for certain patients with advanced prostate cancer. Discuss with your physician whether clinical trials for follow-on therapy align with your current treatment plan and health goals.
Further reading
Learn more about the latest innovations in Cancer care and research.
More information
Review the full Re-LuPSMA clinical trial study details on the official registry.
Source note: This article includes information reported by OncLive.
Live Poll
Do you believe the potential benefits of new cancer therapies justify their reported side effects?
